18 Hospital Physician Board Review Manual www.turner-white.com
and twice-weekly bortezomib in patients with systemic AL
amyloidosis: results of a phase 1 dose-escalation study.
83. Venner CP, Lane T, Foard D, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is
associated with high clonal response rates and prolonged
progression-free survival. Blood 2012;119:4387–90.
84. Jaccard A, Comenzo RL, Hari P, et al. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment of naive patients with high risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica 2014; 99:
85. Dispenzieri A. How I treat POEMS syndrome. Blood 2012;